Q&A with Paul Weiss's Andrew Forman

Andrew Forman, a partner at Paul Weiss Rifkind Wharton & Garrison, has been part of the team at the centre of the Anthem/Cigna merger fight, but it is just the latest healthcare matter on his resume. While his headline-grabbing representations in private practice range from the US Airways/American Airlines tie-up to Eli Lilly's acquisition of Novartis Animal Health, as an attorney in the Mergers I shop of the Federal Trade Commission’s Bureau of Competition, he scrutinised deals in the pharmaceutical and medical device sectors, as well as others.

Unlock unlimited access to all Global Competition Review content